

Neues zur Therapie des frühen Mammakarzinoms (S. 8–17)

C. Jackisch

Literatur:

1. Whelan T et al. LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). J Clin Oncol 2022, 40:(suppl 16, abstract LBA 501)
2. Fernandez-Martinez A et al. Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO and NSABP B-14 Trials. J Clin Oncol 2022, 40:(suppl 16, abstract 509)
3. Pusztai L et al. Event-Free Survival by residual cancer burden after neoadjuvant Pembrolizumab + Chemotherapy vs. Placebo + chemotherapy for Early-Stage TNBC: Explorative Analysis from KEYNOTE-522. J Clin Oncol 2022, 40:(suppl 16, abstract 503)
4. Symmans WF et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4412–22
5. Spring L et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial. J Clin Oncol 2022, 40:(suppl 16, abstract 512)
6. Denkert C et al. Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers. J Clin Oncol 2022, 40:(suppl 16, abstract 583)
7. Huppert LA et al. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. J Clin Oncol 2022, 40:(suppl 16, abstract 504)
8. Brian E et al. Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial. J Clin Oncol 2022, 40:(suppl 16, abstract 500)
9. Tesch M et al. Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa). J Clin Oncol 2022, 40:(suppl 16, abstract 524)
10. Jonson K et al. The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer. J Clin Oncol 2022, 40:(suppl 16, abstract 532)
11. Sawaki M et al. Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. J Clin Oncol 2022; 38(32): 3743–52
12. Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node negative, HER2-positive breast cancer. N Engl J Med 2015 372:134–41
13. Gnant M et al. Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. J Clin Oncol 2022, 40:(suppl 16, abstract 507)
14. Pfeiler G et al. Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial. J Clin Oncol 2022, 40:(suppl 16, abstract 518)
15. Tolaney SM et al. Adjuvant abemaciclib for high-risk early breast cancer (EBC): Factors increasing the rate of treatment discontinuations (TTD) in monarchE. J Clin Oncol 2022, 40:(suppl 16, abstract 527)

Aktuelle Trends in der Kopf-Hals-Onkologie (S. 18–21)

C. Reichel

Literatur:

1. Flach et al. Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC. ASCO 2022, abstract #6017
2. Argiris et al. A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305. ASCO 2022; abstract #6026
3. Liu et al., Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open-label, single-arm, phase Ib clinical trial. ASCO 2022; abstract #6023
4. Hecht et al. Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial. ASCO 2022; abstract #6064
5. Clump et al. A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN). ASCO 2022; abstract #6007
6. Scheff et al. The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). ASCO 2022; abstract #6044
7. Fisher et al. Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). ASCO 2022; abstract e18033
8. Haderlein et al., Deintensification of postoperative radiotherapy in head and neck cancer independent of human papillomavirus status: Results of a prospective multicenter phase II trial. ASCO 2022; abstract #6009
9. Huang et al. Impact on xerostomia for patients with nasopharyngeal carcinoma treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study. ASCO 2022; abstract #6059
10. Sun et al. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial. ASCO 2022; abstract #6001
11. Chen et al. Efficacy and safety of chemotherapy plus subsequent locoregional radiotherapy and toripalimab in de novo metastatic nasopharyngeal carcinoma. ASCO 2022; abstract #6025
12. Huang et al. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study. ASCO 2022; abstract e18032
13. Chen et al. Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial. ASCO 2022; abstract #6068
14. Liang et al. Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage T_{any}N3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial. ASCO 2022; abstract #6012
15. Chen et al. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study. ASCO 2022; abstract e18031

16. Tang et al. Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial. ASCO 2022; abstract #6042
17. Cai et al. Anlotinib for patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II study. ASCO 2022; abstract e18020
18. Yang et al. A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF- β , in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). ASCO 2022; abstract #6024
19. Chiang et al. Antitumor activity of bintrafusp alfa in previously treated patients with recurrent or metastatic nasopharyngeal cancer (NPC): A single arm, prospective phase II trial. ASCO 2022; abstract e18029
20. Lee et al. Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11). ASCO 2022; abstract #6018
21. Patel et al. BTCRC-HN17-111, A phase 2 trial of ADT (goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor (AR). ASCO 2022; abstract e18091
22. Rack et al. The prevalence and prognostic impact of mutations promoting chromatin remodelling dysregulation in non-resectable or recurrent/metastatic adenoid cystic carcinoma. ASCO 2022; abstract #6087
23. Kang et al. A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC). ASCO 2022; abstract #6020
24. Ferrarotto et al., A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC). ASCO 2022; abstract #6019
25. Drilon et al. Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer. ASCO 2022; abstract #3100

Highlights zum Kolorektalen Karzinom (S. 22–25)

M. Collienne, D. Arnold

Literatur:

1. Grothey A. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. *N Engl J Med* 2018; 378(13): 1177–88
2. Iveson TJ. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. *J Clin Oncol* 2021; 39(6): 631–41
3. Tie J. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *N Engl J Med* 2022; 386(24): 2261–72
4. Tie J et al. Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. *J Clin Oncol* 2022; 40(17_suppl), LBA100
5. Yoshino T et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. *J Clin Oncol* 2022; 40(17_suppl), LBA1
6. Heinemann V et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014; 15(10): 1065–75
7. Venook AP et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. *JAMA* 2017; 317(23): 2392

8. Douillard JY et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. *Ann Oncol* 2014; 25(7): 1346–55
9. Stintzing S, Heinemann V. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. *Lancet Oncol* 2016; 17(10): 1426–34
10. Cremolini C et al. Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO. *J Clin Oncol* 2022; 40(suppl 17; abstr LBA3505)
11. Cremolini C et al. Individual patient data meta-analysis of folfoxiri plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. *J Clin Oncol* 2020; 38(28): 3314–24
12. Rahbari NN et al. Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. *J Clin Oncol* 2022; 40(suppl 17; LBA3507)
13. Hospers G et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial. *J Clin Oncol* 2020; 38(15 suppl; 4006)
14. Conroy T et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. *J Clin Oncol* 2020; 38(15 suppl; 4007)
15. Bach SP et al. STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer? *J Clin Oncol* 2020; 40(16 suppl; 3502)
16. Cercek A et al. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. *J Clin Oncol* 2022; 40(17 suppl; LBA5)
17. Cercek A et al. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. *N Engl J Med* 2022 ;386(25): 2363–76
18. André T et al. Pembrolizumab in Microsatellite–Instability–High Advanced Colorectal Cancer. *N Engl J Med* 2020; 383(23): 2207–18
19. Chalabi M et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. *Nat Med* 2020; 26(4): 566–76
20. Verschoor YL et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. *J Clin Oncol* 2022; 40(16 suppl; 3511)